R. Shah

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni et al. · Annals of Oncology · 2020 · 273 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial

Enriqueta Felip, Sanjay Popat, Urania Dafni et al. · Annals of Oncology · 2025 · 22 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM).

Rabab Gaafar, Adolfo Favaretto, Vanesa Gregorc et al. · Journal of Clinical Oncology · 2015 · 10 citations

Medicine, Oncology, Pharmacology +12